• HOME
• ABOUT MaRS
• THE MaRS CENTRE
• MaRS SERVICES
• EVENTS
• NEWS
• RECOMMENDED RESOURCES

• MaRS Event Series
• Reserve Meeting & Event Space

SESSION THEMES The commercial value of biomarkers and various technology platforms are being fueled by the growth of pharmacogenomics and molecular diagnostics markets, as well as their importance in discovery and development of new therapeutics. However, the path to commercialization is complicated by technology development challenges, regulatory approval uncertainty, and complex evaluations that often need to consider multiple applications. Many issues currently under debate will impact the incentive to pursue the development of a platform technology or the regulatory approval for biomarker IP. Mark Chandler (www.Invotex.com) and Dr Bob Morrison (www.BioInvension.com) have years of experience consulting with biotechs, venture capitalists and tech transfer offices internationally on IP and evaluation issues. Their presentation will focus on real-world case studies of IP evaluations, protection and commercialization of technology platforms, biomarkers, as well as drugs coupled with predictive tests that may have applications in personalized medicine. They will offer potential solutions to value issues such as patent pools and other unconventional commercialization strategies. Mark and Bob wish to make this session as interactive as possible and, as such, are leaving extra time in their presentation to discuss your IP evaluations and commercialization challenges in these areas.

DATE | TIME | LOCATION

AGENDA

ABOUT THE SPEAKERS

Mark Chandler is the Managing Director of Invotex Group, a US-based firm specializing in financial, accounting and intellectual property (“IP”) consulting services. Mark leads the firm’s activities in IP transactions, valuation and financing. Mark has more than twenty years experience in the development, management and commercialization of advanced technology, specializing on IP assets for the past eleven years. Prior to Invotex, Mark led corporate venturing activities for BTG plc, a UK-based technology investment and development firm. He has been involved in the creation or funding of over ten new venture-backed companies in North America and Europe, all based around IP assets. Mark received his Bachelor’s Degree in Electrical Engineering from Bucknell University and a Masters in Business Administration from the Wharton School of the University of Pennsylvania.

Robert Morrison is Principal and Managing Director of Bioinvension, a specialty consulting firm focused on technology management in the life sciences. Bioinvension provides services to companies and academic institutions in support of their business development and licensing efforts. Bioinvension also supports investors and analysts via custom research. Prior to founding Bioinvension, Dr. Morrison was Senior Vice President, Strategic Business Development for BTG plc, leading efforts in licensing molecular diagnostics and other biotechnologies. Before joining BTG, Dr. Morrison was Director of Global Biotechnology for American Cyanamid and BASF with responsibility for development of a comprehensive biotechnology platform.

• Email Page
• Print Page
• Increase Font
• Decrease Font

MaRS PICKS

Read more

See more picks

See more picks

• MaRS Centre, South Tower, 101 College Street, Suite 100
• Toronto, ON Canada M5G 1L7
• T 416.673.8100F 416.673.8181E marsdiscoverydistrict@marsdd.com

• Copyright 2007 MaRS Discovery District. All rights reserved.


• Contact MaRS
• Site Map
• Privacy Policy
• Terms and Conditions